DEALS
Zhong Lun Assists Ribo Life in its Hong Kong Listing
Zhong Lun Assists Ribo Life in its Hong Kong Listing
On January 9, 2026, Suzhou Ribo Life Science Co., Ltd. (“Ribo Life”, 6938.HK) successfully completed its initial public offering (“IPO”) of shares and was listed on the Main Board of The Stock Exchange of Hong Kong Limited under Chapter 18A of the Listing Rules. Prior to the exercise of the over-allotment option, the offering price of Ribo Life was HKD 57.97 per share, raising total gross proceeds of approximately HKD 1.83 billion.
In this listing, Zhong Lun Law Firm acted as the PRC legal advisor to the client’s H shares’ issuance and full circulation, providing end-to-end, integrated legal services, garnering acclaim form the client and all parties involved. The signing lawyers handling this project were Yiwen Chen (partner), Jia Liu (partner), and Xiaobao Chang (associate). Key members of the project team also included associates Mengqi Lan and Xin Du, among others. This project was managed by partner Zhong Zhang.
Ribo Life is a biopharmaceutical company engaged in oligonucleotide research and development, with a focus on siRNA therapeutics. Leveraging its proprietary and fully independently owned intellectual property rights in the RiboGalSTAR™ liver-targeted delivery platform, the company has established a robust pipeline of proprietary research and development products. Specifically, among a pipeline of seven in-house discovered drug assets in clinical trials for seven indications across cardiovascular, metabolic, renal, and liver diseases, four are in phase 2 clinical trials. RBD4059 (FXI-targeting siRNA), the company’s core product, is the world’s first clinical-stage siRNA drug that targets thrombotic diseases. In addition, Ribo Life is also advancing other clinical-stage candidates, including RBD5044 and RBD1016. Notably, RBD5044 is the second siRNA globally to enter clinical development that targets APOC3, a protein that plays a role in lipid metabolism.
